ORTEC
16.1.2024 15:31:30 CET | Business Wire | Press release
ORTEC, a global provider of decision support software and data science capabilities, is pleased to announce a partnership with investment firm Battery Ventures to accelerate its growth ambitions. This strategic partnership, including a significant investment by Battery, marks a key moment in ORTEC’s existence and positions the company to increase its impact on customers and in core markets globally. With this partnership, ORTEC will be able to further strengthen its leadership position in the US and Europe in the field of supply chain, workforce-management and data science & consulting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116805637/en/
Michael van Duijn (ORTEC CEO) and Zak Ewen (Partner Battery Ventures) (Photo: Business Wire)
Improving the world through data and mathematics
The ORTEC journey started in the early 1980s, when a few passionate Dutch students wanted to show the world the value of mathematics by creating long-term sustainable growth for organizations and society. Specifically, the company’s initial consulting business helped customers leverage data and mathematical models to solve operational problems. Over time, the company developed commercial products that help large enterprises address complex logistical challenges such as last-mile fleet dispatch and route planning; pallet-load planning and optimization; and advanced workforce scheduling and resource planning.
Now, more than 40 years later, ORTEC delivers solutions to over 1,200 customers worldwide to improve business results and make a positive impact on the world. Customers include ASML, Heineken, Coca-Cola Enterprises, Procter & Gamble, Shell, Waitrose, Albert Heijn, G4S, Sodexo and Tesco.
In partnership with Battery, going forward, ORTEC will offer products and services through three new divisions that focus on logistics and routing solutions, workforce-management solutions, and data science and consulting. Battery, which was founded in 1983, is a longtime, global software investor that has made more than 500 investments over the last four decades.
“We are very pleased that Battery Ventures joins ORTEC as a strategic partner. With their knowledge, experience, and network, we can further drive innovation, expand our market reach and create additional impact for our customers,” said Michael van Duijn, ORTEC’s chief executive. “I am proud of the great company we are today and the amazing group of talented employees that create impact for our customers day in and day out. It makes me excited that with this partnership, we have the ingredients to make a more positive impact on the world.”
Shared commitment to long-term growth
The agreement between ORTEC and Battery Ventures highlights a shared commitment to drive innovation, deliver exceptional value to customers, and achieve long-term impact growth. Both parties are confident that the partnership will pave the way for ORTEC to expand its strong position as a leading provider of optimization technology built to solve complex operational challenges in an increasingly data-driven world.
“We’ve gotten to know ORTEC and its founding team over a period of more than 10 years, and during that time we’ve watched the business transform from a consulting-led business into a commercial software company serving the world’s most sophisticated and complex enterprises,” said Zak Ewen, a Battery partner based in London, who joins ORTEC’s board. “Now we’re excited to formally partner with Michael, Aart, Gerrit and the rest of the team to further accelerate the company’s mission.”
Moving forward, ORTEC founders Aart van Beuzekom and Gerrit Timmer remain part of the board and will continue to take care of ORTEC and its future.
About ORTEC
For more than 40 years ORTEC has been supporting many of the world’s best-run organizations to make better data-driven decisions. Our decision support software and data science capabilities enable our customers to improve their business results and make a positive impact on the world. With our 1,000 employees across 13 countries, we help over 1,200 leading customers worldwide to make better choices in an ever-changing environment. Discover more at www.ortec.com.
About Battery Ventures
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Herzliya, Israel; London; and New York. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116805637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom